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Abstract
Background: Reports indicate that PDLIM5 is involved in mood disorders. The PDLIM5 (PDZ and LIM domain 5) gene has
been genetically associated with mood disorders; it’s expression is upregulated in the postmortem brains of patients with
bipolar disorder and downregulated in the peripheral lymphocytes of patients with major depression. Acute and chronic
methamphetamine (METH) administration may model mania and the evolution of mania into psychotic mania or
schizophrenia-like behavioral changes, respectively.
Methods: To address whether the downregulation of PDLIM5 protects against manic symptoms and cause susceptibility to
depressive symptoms, we evaluated the effects of reduced Pdlim5 levels on acute and chronic METH-induced locomotor
hyperactivity, prepulse inhibition, and forced swimming by using Pdlim5 hetero knockout (KO) mice.
Results: The homozygous KO of Pdlim5 is embryonic lethal. The effects of METH administration on locomotor hyperactivity
and the impairment of prepulse inhibition were lower in Pdlim5 hetero KO mice than in wild-type mice. The transient
inhibition of PDLIM5 (achieved by blocking the translocation of protein kinase C epsilon before the METH challenge) had a
similar effect on behavior. Pdlim5 hetero KO mice showed increased immobility time in the forced swimming test, which
was diminished after the chronic administration of imipramine. Chronic METH treatment increased, whereas chronic
haloperidol treatment decreased, Pdlim5 mRNA levels in the prefrontal cortex. Imipramine increased Pdlim5 mRNA levels in
the hippocampus.
Conclusion: These findings are partially compatible with reported observations in humans, indicating that PDLIM5 is
involved in psychiatric disorders, including mood disorders.
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Introduction
The PDLIM5 gene encodes the enigma homolog (ENH). In
total, 4 known isoforms of the human PDLIM5 protein have been
identified: ENH1, ENH2, ENH3, and ENH4. The largest isoform,
ENH1, contains 1 PDZ (postsynaptic density-95/discs large/zone
occludens-1) domain and 3 LIM (Lin-11, Isl-1, and Mec-3)
domains at the C-terminal end [1]. ENH1 is expressed in various
tissues, such as the heart, brain, spleen, liver and kidney. In
comparison, shorter isoforms that lack the LIM motifs are
expressed in cardiac (ENH3) and skeletal muscle (ENH2,
ENH3, and ENH4) [1,2,3]. ENH1 is expressed in various regions
of the brain, including the hippocampus, cortex, thalamus,
hypothalamus, amygdala, and cerebellum [4].
ENH1 was originally identified as a PKC-interacting protein [1]
and which may activate conventional PKCs by directly binding
them through its LIM domains [5]. The ENH1 LIM domain is
one of the targets of protein kinase C (PKC), which has been
shown to bind to the regulatory domain of PKCb1 and e? [1,4].
ENH has been shown to be localized in the presynaptic nerve
terminals [4,6] and in the postsynaptic density [7]. ENH has been
reported to interact with CaV2.2, which is a presynaptic calcium
channel type that is known to be sensitive to enhancement by PKC
[4] and may be an adaptor for the regulation of intracellular
calcium levels by constructing a PKCe–ENH–N-type Ca2+
channel complex [8]. However, the mechanism by which ENH
and Cav2.2 interact remains controversial [6]. In the postsynaptic
density, PDLIM5 is reported to interact with spine-associated
RapGAP (SPAR, SIPA1L1), and to promote the shrinkage of
dendritic spines [7]. RNA interference against PDLIM5, or loss of
PDLIM5 interaction with SPAR, causes an increase in spine head
diameter. PKC activation promotes the delivery of PDLIM5 into
the dendritic spines and increases its spine co-localization with
SPAR [7].
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Recent studies have shown that SNPs in the PDLIM5 gene are
associated with schizophrenia [9,10,11], bipolar disorder
[10,12,13], and major depression [14,15]. In contrast, other
studies have reported no significant genetic association between
the PDLIM5 gene and schizophrenia [16,17]. However, the
associations have been replicated in independent populations with
bipolar disorders [12,13] and major depression [15].
The precise molecular roles of PDLIM5 in mood disorders
remain unclear. An association between the SNP rs2433320 and
bipolar disorders confirmed by a meta-analysis [12] was also
observed in the genome-wide association study carried out by The
Wellcome Trust Case Control Consortium (WTCCC) (p= 0.03)
[18]. The SNP rs2433320, which is located approximately 2 kb
upstream of PDLIM5, was reported to be associated with PDLIM5
mRNA levels in the prefrontal area [9]. Iwamoto and colleagues
used DNA chip analysis to examine the prefrontal regions of
postmortem brains of patients with mental disorders, and found
that PDLIM5 was upregulated in patients with schizophrenia,
bipolar disorder and major depression [19]. The upregulation of
PDLIM5 in the prefrontal cortex and cerebellum has also been
show by the Stanley Medical Research Institute Online Genomics
Database for schizophrenia (p= 0.037) and for bipolar disorder
(p= 0.38), though it did not show significant upregulation for
bipolar disorder (https://www.stanleygenomics.org/stanley/
geneDetail.jsp?gene_id = 7370). The PDLIM5 mRNA expression
levels in the peripheral leukocytes of medication-free patients with
schizophrenia were significantly higher than in those of control
subjects [16]. In contrast, decreased peripheral PDLIM5 mRNA
expression in whole blood from manic patients with bipolar
disorder type I was reported [20]. The authors also reported no
significant difference in PDLIM5 mRNA expression following
treatment with olanzapine treatment while reducing in the severity
of manic symptoms [20]. In addition, significantly lower PDLIM5
mRNA expression levels have been reported in the peripheral
leukocytes of drug-naı¨ve patients with depression than in those of
control subjects. Furthermore, after 4 weeks of paroxetine
treatments, PDLIM5 mRNA expression significantly increased to
almost the same level as the control subjects [17]. Thus, studies on
PDLIM5 expression have shown variable results when using
postmortem brains and peripheral leukocytes in patients with
mood disorders. It should be noted that there is a difference in the
expression level of the PDLIM5 gene in the peripheral blood cells
of patients with major depressive disorder and schizophrenia who
were undergoing treatment with antidepressants and antipsychot-
ics [16,17].
In terms of PKC activity, which is mutually regulated by ENH1,
the prefrontal cortex of postmortem subjects with major depres-
sion exhibited significantly lower protein expression of PKCb1
and PKCe compared to controls [21]. Postmortem studies have
demonstrated that membrane-associated PKC and the stimula-
tion-induced translocation of the cytosolic enzyme to the
membrane increased in the frontal cortex of patients with bipolar
disorder [22,23]. A significant increase in membrane-associated
platelet PKC activity has been demonstrated in manic patients,
while enhanced PKC activity during mania is suppressed by
mood-stabilizer treatments [24,25,26]. In comparison, decreased
PKC activity and PKCbI and bII levels, but not PKCa or PKCf,
in the membrane and cytosol fractions of platelets from
medication-free pediatric patients with bipolar disorder has been
reported [27]. In general, many other studies support the
involvement of PKC and its substrates in the pathophysiology of
bipolar disorders and their use in the treatment of bipolar
disorders [28,29,30,31,32].
Thus, the links between PDLIM5 expression and mood
disorders, and between PKC and mood disorders, have been
reported in humans, while the link between PDLIM5 and PKC
has been reported for cell and in-vitro experiments. However, the
experimental analysis of lowered Pdlim5 expression and the
disruption of PKCe translocation on mood disorder in mouse
models have not been reported. To obtain insights about the
effects of PDLIM5 expression on the whole body of individuals
with mood disorders, we examined the effects of constitutionally
reduced levels of the ENH1 isoform of PDLIM5 generated by the
ENH1 isoform of Pdlim5 knockout (KO) mice on behaviors
associated with mania and depression. Because it has been
acknowledged that single-dose methamphetamine (METH) treat-
ment and chronic METH treatment may model mania and the
evolution of mania into psychotic mania or schizophrenia-like
behavioral changes, respectively [33], we evaluated behaviors in
response to METH treatments in Pdlim5 hetero KO mice. The
mood stabilizers lithium and valproate are known to reverse
METH-induced hyperactivity and behavioral sensitization
[34,35,36].
In addition, we evaluated the effects of administrating the
PKCe-translocation inhibitor peptide (PKCe-TIP) on the response
of mice to METH. The LIM domains of PDLIM5 have been
identified as interaction sites for various PKCbI and e isoforms,
while the V1 region of PKC has been identified as critical for
PDLIM5-PKC interaction [1]. PKCe-TIP, which is a small water-
soluble peptide (8 amino acid residues) derived from the V1 region
of PKCe [37], may specifically inhibit the effects of PKCe by
blocking the translocation of PKCe from the cytosol to the
membrane [4]. PKCe-TIP has been used to specifically inhibit the
effects of PKCe in in vivo experiments [38].
As a parameter of depressive behavior, we examined the
immobilization of Pdlim5 hetero KO mice in a forced swimming
test, with and without the administration of imipramine.
Materials and Methods
Generation of Pdlim5-deficient Mice and the Mice Used
in This Study
The mouse Pdlim5 gene-trapped ES cell line (XH199) was
obtained from the Mutant Mouse Regional Resource Center
(http://www.mmrrc.org/). The Pdlim5 gene, which contains 13
exons, specifies a PDZ domain and 3 LIM domains. Exon 2 of
Pdlim5 specifies the end of the PDZ domain, while exon 9 specifies
the beginning of the first LIM domain. The gene-trap vector,
pGT1lxf containing the Engrailed 2 (En2) splice acceptor sequence,
b-geo (b-galactosidase/neomycin phosphotransferase fusion gene)
and a SV40 poly (A) signal sequence generated a mature Pdlim5
(exons 1–8)- b-geo mRNA, which was determined by 59 RACE
PCR at BayGenomics (http://baygenomics.ucsf.edu/). Thus,
incorporation of the gene trap generates a fusion between the
PDZ and the b-geo gene products (Fig. 1A–D), which contains 1–
368 amino acids (aa) of the ENH1 isoform and 1–306 aa of the
ENH2 isoform. The ES cell line was injected into C57BL/6J host
blastocysts to generate chimeras. The chimeras were then crossed
with C57BL/6J mice to determine germ line transmission. Total
RNA and DNA were extracted from the tail tissues by using
ISOGEN (WAKO, Tokyo, Japan). cDNA was synthesized using
ReverTra Ace (Toyobo, Tokyo, Japan) and oligo dT primers.
Genotype detection was carried out by PCR of cDNA by using 3
primer methods. To detect the 59 end of the gene trap insertion,
the primers used were as follows: Pdlim5_exon8Fc: 59-CAC-
CAGCGTCAAGTCACCTA-39, bgeoRc: 59-ATTCAGGCTG-
CGCAACTGTTGGG-39, and Pdlim5_exon9Rc: 59-TGCA-
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CAAGTGTGTCTTGGTCAC-39. Routine genotyping was car-
ried out by PCR of genomic DNA by using the following primers:
bgeoR: 59-ATTCAGGCTGCGCAACTGTT-39, Pdlim5_ex8F:
59-CACCAGCGTCAAGTCACCTA-39, Pdlim5_exon9R: 59-
TGCACAAGTGTGTCTTGGTCAC-39, and Pdlim5_exon9F:
59-CCGCCTAGTGTTTGCATCATAA-39.
The animals were housed under a 12-h light/12-h dark cycle,
with constant temperature (25uC) and humidity, and were allowed
free access to food and water. All animal procedures were
performed according to protocols approved by the Animal Care
and Use Committee of the University of Tsukuba, Japan.
Unless otherwise specified, 6- to 8-week-old male mice were
used in this study; the mice were derived from 6 to 8 backcrosses
(N6,N8) to C57BL/6J (Charles River Laboratories Japan,
Yokohama, Japan) from the chimera (129 X C57BL/6). Each
behavioral experiment was performed independently using a new
group of animals, except for novelty-seeking, rota-rod, social
interaction, and prepulse inhibition tests without drug adminis-
tration. These tests were performed consecutively every week in
this order, using mice of the N6 backcross generation; however,
the number of mice tested differed among each of these tests.
Analysis of Pdlim5 Transcription in the Brain Tissue of
Mice
The prefrontal cortex, midbrain, hippocampus, thalamus, and
striatum were removed by dissection. Total RNA was then
extracted from the brain tissues with ISOGEN Reagent (Nippon
Gene Co, Tokyo, Japan). Pdlim5 cDNA was synthesized with
ReverTra Ace (Toyobo) and the oligo dT primer from RNA.
Expression was quantified by real-time quantitative PCR analysis
with the TaqMan Gene Expression Assay and ABI PRISM
7900HT Sequence Detection System (Applied Biosystems, Foster
City, CA), according to the manufacturer’s instructions. Primers
and probes were purchased from Applied Biosystems (Assay ID:
Mm00517301_m1). Rodent glyceraldehyde-3-phosphate dehydro-
genase (Gapdh) was used as an internal control, and the threshold
cycle (Ct) was measured in triplicate. Data were collected and
analyzed with Sequence Detector Software (SDS) version 2.2.2
(Applied Biosystems). The relative gene expression was calculated
as the ratio of Pdlim5 to the internal control Gapdh. The Ct
measurement was the average of 3 replicates. Six wild-type and 8
heterozygous, 8-week-old male mice of the N3 backcross
generation were used in this Pdlim5 transcriptional analysis.
Figure 1. Gene-trap mutagenesis of Pdlim5. (A) Insertion site of the gene-trap cassette in intron 8 of the Pdlim5 gene. The inserted sequence
(gray box) includes a splice acceptor (SA), b-geo, which is a fusion of b-galactosidase and neomycin phosphotransferase II, and is followed by a stop
codon and a polyadenylation signal (pA). (B) Schematic of the gene trap cassette. C) RT-PCR results and genomic genotyping of Pdlim5+/+,
Pdlim5+/2. Samples were extracted from the brain and tail. (D) Expected domain structures of wild-type and PDLIM5 mutant proteins. (E) Real-time
PCR analysis of Pdlim5 in the prefrontal brains of Pdlim5+/+ (n = 6) and Pdlim5+/2 (n = 8) mice [F(1, 12) = 14.0, p= 0.003]. Values are shown as mean6
SD. (F) Representative western blots of Pdlim5 in the prefrontal brains of Pdlim5+/+ and Pdlim5+/2.
doi:10.1371/journal.pone.0059320.g001
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Western Blot Analysis
Protein was extracted from brain tissue with Laemmli buffer.
The concentration of total protein was measured by using a
Wallac 1420 ARVOsx multilabel counter (Perkin Elmer, Yoko-
hama, Japan). Then, 2 mg of each sample was run on a Pro-
PureTM SPRINT NEXT GEL (Amresco, Solon, OH) and
transferred to BioTraceTM PVDF (Nihon Pall Ltd., Tokyo, Japan).
Human PDLIM5 Polyclonal Antibody (1:100dilution) (MBL,
Nagoya, Japan) was used as the primary antibody, or polyclonal
antibody to beta-Actin (1:500 dilution) (Imgenex, San Diego, CA)
for normalization. Bound primary antibodies were detected with
goat anti-rabbit IgG antibody HRP conjugate (MBL) in 1:10000
dilution and ImmobilonTM Western Chemiluminescent HRP
Substrate (Millipore, Billerica, MA) by LAS-4000UVmini (Fuji-
film, Tokyo, Japan). LAS-4000UVmini directly measures the
amount of both proteins on the membrane, and facilitates the
calculation of relative Pdlim5 expression among subjects. Six wild-
type and 8 heterozygous, 8-week-old mice of the N10 backcross
generation were used in this Pdlim5 western blot analysis.
Drugs and Administration Schedule
METH (Dainippon Sumitomo Pharma Co., Ltd, Osaka, Japan)
was dissolved in saline solution. The acute METH treatment
group received a single dose of METH injection (3 mg/kg,
intraperitoneal [i.p.]). The chronic METH treatment group was
generated by the injection of 1 mg/kg METH after i.p. injection
of 3 mg/kg METH once daily for 14 days and a subsequent 14-
day withdrawal period. This chronic treatment developed
behavioral sensitization to METH, which was confirmed by
1 mg/kg injection of METH. Haloperidol was dissolved in 0.9%
saline solution with tiny drops of lactate, and was administered
(1 mg/kg, i.p.) daily for 7 weeks. Imipramine was dissolved in
saline solution and administered (20 mg/kg, i.p.) daily for 14 days.
The control group for each experiment received saline injections.
Locomotor Activity Analysis
To evaluate the behavioral effects of METH treatment,
spontaneous horizontal locomotor activity was measured using
the Lime Light (Actimetrics, Wilmette, IL) CCD camera tracking
system. The mice were placed inside soundproof and illuminated
plastic cages (40 cm6 20 cm6 20 cm). Each mouse was placed
separately in a box for a 60-min habituation period. Spontaneous
activity was recorded for 60 min (habituation to the experimental
procedure), and then the mice were injected with i.p. METH or
saline solution, and locomotor activity was recorded for an
additional 120 min immediately after injection. The total distance
traveled was recorded. The effects of acute METH treatment on
locomotor activity were measured for 13 wild-type and 13
heterozygous mice, and the effects of chronic METH treatment
on locomotor activity was measured for 11 wild-type and 23
heterozygous mice. Locomotor activity without drug treatment
was measured in 4 wild-type and 6 heterozygous mice.
Acoustic Startle Response (Prepulse Inhibition, PPI) Test
PPI refers to the reduction in the startle response produced by
the antecedent presentation of a low-intensity non-startling
stimulus, representing sensorimotor gating [39]. Sensorimotor
gating deficits in patients with schizophrenia, as indexed by
measures of PPI, have been well characterized and are suggested
as meeting the criteria of a useful endophenotype in human
genetic studies [40]. With respect to bipolar disorder, current
research suggests that PPI deficiency is state dependent rather than
a constant trait. Patients with bipolar disorder with acute mania
symptoms and psychosis exhibit PPI deficits [41]. PPI is measured
using an SR-Lab system (San Diego Instruments Inc., San Diego,
USA). Wild-type and hetero KO male mice (age, 6–8 weeks) were
pre-treated intraperitoneally with saline or METH (1 mg/kg)
5 min before testing. After treatment, they were placed in a
Plexiglas cylinder test chamber. Experimental sessions consisted of
a 5-min acclimatization period with 70-dB broadband background
noise, which was continuous throughout the session, followed by
three 120-dB acoustic pulses and PPI sessions. Sessions consisted
of 10 blocks of 5 different trial types: startle pulse alone with a 40-
ms duration at 120 dB (P120); and 4 prepulse+pulse trials with a
20 ms duration prepulse at either 78 dB (PP78), 82 dB (PP82), or
86 dB (PP86) followed by a 40-ms duration startle stimulus at
120 dB after a 100-ms delay. These were carried out in a
pseudorandom order, with an average intertrial interval of 15 s.
The startle response was recorded as maximum startle amplitude.
PPI was calculated as a percentage score for each prepulse
intensity, using the following equation: %PPI = 1006 [(mean
startle amplitude on pulse-alone trials – mean startle amplitude on
prepulse trials)/mean startle amplitude on pulse-alone trials]. The
startle magnitude was calculated as the average of all pulse-alone
(p120) trials, excluding the first 3 p120 trials in each session. The
effects of acute METH treatment on PPI were measured in 11
wild-type and 13 heterozygous mice, and the effects of chronic
METH treatment on PPI was measured for 12 wild-type and 24
heterozygous mice. PPI without drug administration was mea-
sured for 10 wild-type and 10 heterozygous mice.
Forced Swimming Test
The forced swimming test was performed according to the
method of Porsolt et al. (1977), with minor changes. The day
before the test, mice were anesthetized with isoflurane, and wire
rings (0.28 mm in diameter, 1.5 cm in length, and 10 mg in
weight) were attached to both hind paws. A small magnet (1 mm
in diameter, 3 mm in length) was attached to each of the wire
rings. After a 12- to 18-h habituation, mice were subjected to
forced swimming tests. Narrow plastic cylinders (18 cm in height,
11 cm in diameter) were filled with water (maintained at 2561uC)
to a depth of 10 cm. The cylinders were located in a MicroAct
(Neuroscience Inc., Tokyo, Japan; see Inagaki et al. 2002)
behavioral measuring system, which allowed the detection of
motion by registering electric currents induced in a magnetic coil
surrounding the cylinder by using magnets attached to the limbs of
the mice. Mice were placed in the cylinders and motion was
recorded for 6 min. The mice were judged immobile whenever
they floated passively in the water; the judgment was based on
threshold values. Electrical signals meeting the following criteria
were classified as swimming: signals greater than 100 mV that
continued for more than 0.1 s without gaps of more than 1.0 s.
Immobility time was measured during the last 4 min of the 6-min
session. Imipramine (20 mg/kg) or saline was injected for 14 days,
and the test was performed 40 min after the last injection. The
forced swimming test was performed on 24 wild-type and 9
heterozygous, 8-week-old male mice of the N8 backcross
generation after saline injection, and on 12 wild-type and 12
heterozygous mice after imipramine injection.
Rota-rod, Novelty-seeking, and Social Interaction Tests
Rota-rod, novelty-seeking, and social interaction tests were
carried out according to the methods described in the published
literature [42,43]. The rota-rod tests were performed in 10 wild-
type and 20 heterozygous mice, the novelty-seeking tests were
performed on 24 wild-type and 41 heterozygous mice, and the
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social interaction tests were performed on 8 wild-type and 21
heterozygous mice.
Surgery and Intracerebroventricular Infusion Procedure
Mice were anesthetized with sodium pentobarbital (40 mg/kg,
i.p.), and mounted in a stereotaxic frame. A stainless steel guide
cannula (23 gauge) was placed into the lateral ventricle (AP,
0.46 mm; ML, 1.01 mm to the bregma) for subsequent intracer-
ebroventricular (icv) infusion. The guide cannula extended
4.0 mm below the surface of the skull. One Anchor Screw
(EICOM, Kyoto, Japan) was placed into the skull and dental
cement was poured over the exposed skull to hold the screws and
cannula in place and close the incision site. A dummy cannula was
placed into the guide. Mice were allowed to recover for 3 days
prior to testing. Cannula placement was assessed in random
animals via the icv infusion of xylene cyanol and the verification of
dye in the ventricular system.
During infusions, the dummy cannulas were removed. An
infusion cannula (30 gauge), which was attached to PE 20 tubing,
was inserted into the guide cannula. A 10.0-ml Hamilton syringe
was used to manually deliver Ringer’s solution or PKCe-TIP
(Merck KGaA, Darmstadt, Germany) over a 1-minute period.
The infusion cannula was kept in place for an additional 30 s
following infusion. Mice were then replaced into their original
cages. The change in locomotor activity induced by METH
injection was measured in 6 mice infused with Ringer’s solution
infusion and 10 mice infused with PKCe-TIP.
Statistical Analysis
Data were analyzed using JMP software version 7.0.1 (SAS
Institute, Cary, NC, USA). The data of the expression analysis
were analyzed by one-way analysis of variance (ANOVA) followed
by post hoc analysis using a Student’s t test to evaluate the effect of
METH or imipramine administration in each brain area. Effects
of genotype, METH treatment, and imipramine treatment on
behavior were analyzed by ANOVA, followed by post hoc analysis
using a Student’s t test. The results were expressed as the mean 6
SD. A p value ,0.05 was considered significant.
Results
Pdlim5 Deficient Mice
To generate Pdlim5 KO mice, Pdlim5+/2 mice were crossed;
however, Pdlim5 KO mice were not identified among 134
genotyped pups, indicating that null Pdlim5 results in embryonic
lethality. No apparent phenotypic differences were observed
between the wild-type and Pdlim5 hetero KO mice. No significant
difference in body weight, brain size, or brain shape was observed
between Pdlim5+/2 and Pdlim5+/+ mice. Pdlim5 expression levels
in the prefrontal cortex of hetero KO mice (Pdlim5+/2) were less
than 50% of those in the wild littermate mice (Pdlim5+/+) (Fig. 1E).
The expression of PDLIM5 protein decreased in Pdlim5+/2
compared to the wild littermate mice (Pdlim5+/+) (Fig. 1F).
Behavioral Characteristics of Pdlim5 Deficient Mice
No significant difference in rota-rod (Fig. S1A), novelty-seeking
(Fig. S1B), social interaction (Fig. S1C), locomotion (Fig. S1D), or
PPI tests (Fig. S1E) was observed between Pdlim5+/+ and
Pdlim5+/2 mice.
Pdlim5+/2 Mice in Mania Models
Single-dose METH treatment produced an enhancing effect on
spontaneous locomotor activity in mice. The magnitude of
enhanced locomotor activity by an single-dose injection of METH
was significantly lower in Pdlim5+/2 mice than in Pdlim5+/+ mice
when comparing locomotor activities 30 minutes before and after
METH injection [F(1, 24) = 9.4, p= 0.005] (Fig. 2A, 2B). An
injection of METH (3 mg/kg) impaired PPI in Pdlim5+/+ mice,
but did not appear to impair PPI in Pdlim5+/2 mice, leading to
significantly less impairment of PPI in the acoustic startle response
of Pdlim5+/+ mice compared to Pdlim5+/2 mice; ANOVA
revealed a significant main effect of genotype [F(1, 70) = 5.1,
p= 0.03] (Fig. 2C). No significant difference was observed between
the Pdlim5+/2 and Pdlim5+/+ mice for the startle response to
120-dB acoustic stimuli when treated with saline or acute or
chronic METH treatment (data not shown).
The effect of the METH injection (1 mg/kg), after 14-day
treatment with METH (3 mg/kg) and 14 days of subsequent
withdrawal, was also significantly lower in Pdlim5+/2 mice than in
Pdlim5+/+ mice when comparing locomotor activities 30 min
before and after METH injection [F(1, 32) = 6.2, p= 0.02] (Fig. 2D,
2E). An injection of METH (1 mg/kg) also produced significantly
less impairment of the PPI in the acoustic startle response of
Pdlim5+/2 mice compared to Pdlim5+/+ mice; ANOVA revealed
a significant main effect of the genotype [F(1, 106) = 9.3, p= 0.003]
(Fig. 2F).
Effects of PKCe-TIP on Locomotor Activity and PPI
Response to METH
After being treated with 3 mg/kg METH (i.p.) for 14
consecutive days followed by 14 days of withdrawal, 2 mg of
PKCe-TIP or Ringer’s solution was injected via icv fusion for 7
consecutive days. After this treatment, a 1 mg/kg METH
challenge was provided intraperitoneally on the 8th day. PKCe-
TIP treatment produced a weakened locomotor response to
METH injection compared to Ringer’s solution treatment
[F(1,14) = 4.1, p= 0.06] (Fig. 3A, 3B). PKCe-TIP treatment
produced significantly less impairment of the PPI in the acoustic
startle response compared to treatment with Ringer’s solution
[F(1,43) = 4.54, p,0.05] (Fig. 3C).
Pdlim5+/2 Mice in the Forced Swimming Test and the
Effect of Imipramine Treatment
We conducted a forced swimming test, which is a common
behavioral test for assessing depression in rodents and for testing
the efficiency of antidepressant drugs, in Pdlim5 hetero KO mice.
A significant increase in immobility time was observed in Pdlim5
hetero KO mice compared to the wild-type mice when they were
treated with saline [F(1,31) = 7.3, p= 0.01]. Imipramine signifi-
cantly attenuated immobility time in Pdlim5 hetero KO mice [F(1,
16) = 12.0, p= 0.003]. A decrease in immobility time was also
observed in wild-type mice, but was not significant [F(1,33) = 1.5,
p.0.05] (Fig. 4).
Changes in Pdlim5 Expression Levels in Mouse Brains
Following METH, Haloperidol, and Imipramine Treatment
We investigated whether chronic METH administration induc-
es changes in Pdlim5 expression in mouse brains. Pdlim5 expression
levels in the brains were not significantly different in 7-week-old
male mice (C57BL/6J) sacrificed 24 h after 1 dose of i.p. METH
injection (3 mg/kg) or in saline-injected mice [F(5, 44) = 1.9,
p= 0.11]. Pdlim5 expression levels in the brains were significantly
different in mice 24 h after administering the last chronic injection
(3 mg/kg for 14 consecutive days) and mice injected intraperito-
neally with saline [F(5,44) = 4.8, p= 0.001]. Post hoc analysis
revealed higher Pdlim5 expression levels in the prefrontal area of
chronic METH-administered mice than in saline-administered
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mice (p= 0.03; Fig. 5A). The upregulated Pdlim5 expression in the
prefrontal cortex of chronic METH-administered mice was
confirmed by a separate experiment with different mice
(p= 0.01) (Fig. 5B).
Chronic administration of haloperidol did not produce a
significant difference in Pdlim5 expression levels in the overall
brain of mice sacrificed 24 h after administering the last chronic
injection (1 mg/kg for 49 consecutive days) or in mice injected
intraperitoneally with saline [F(5,93) = 1.3, p= 0.27]. However,
post hoc analysis revealed lower Pdlim5 expression levels in the
prefrontal area of mice, and higher Pdlim5 expression levels in the
hippocampus and midbrain after chronic haloperidol administra-
tion compared to mice administered with saline (p= 0.05, 0.009,
and 0.06, respectively; Fig. 5C).
Pdlim5 expression levels in the brains were significantly different
for mice after chronic imipramine administration compared to
mice after 14 days of i.p. saline injection [F(5,45) = 6.3,
p= 0.0002]. Post hoc analysis revealed higher Pdlim5 expression
levels in the hippocampal area of chronic imipramine-adminis-
tered mice than in saline-administered mice (p= 0.03; Fig. 5D).
Pdlim5 expression levels in the brains were not significantly
different for mice administered 1 dose of imipramine compared to
saline-administered mice [F(1, 44) = 1.9, p= 0.11].
Discussion
To our knowledge, this is the first report about Pdlim5 KO mice.
The removal of exons 9–13 eliminates binding determinates for
the LIM domain, consequently disrupting the interaction of PKC.
The targeted Pdlim5 allele generated mice that expressed a fusion
protein lacking the LIM domain, thereby allowing the physiolog-
ical role of the PDLIM5 LIM domain to be assessed. LIM
domains are members of the zinc-binding domain family that is
found in many key regulators of developmental pathways. The
present study identified that embryonic lethality occurs when the
PDLIM5 LIM domain is lost in mice. PDLIM5 is expressed in
various tissues, including the heart, skeletal muscle, brain, lung,
spleen, thymus, prostate, testis, ovary, small intestine, colon,
leukocyte, liver, and kidney [3]. PDLIM5 preferentially interacts
with PKCb through the LIM domains in cardiomyocytes [1], and
has an important role in heart development by scaffolding PKCb
to the Z-disk region [44]. It also binds to PKD1 and interacts with
the cardiac L-type voltage-gated calcium channel subunit alpha1c
in cardiomyocytes [45]. The silencing of Pdlim5 inhibits the alpha-
adrenergic-induced increase of L-type calcium currents [45].
Although we did not examine Pdlim52/2 embryos, the lethal
embryonic phenotypes of Pdlim52/2 mice may have arisen
because of embryonic heart/circulation failure. In zebrafish, ENH
knockdown appears to have a lethal effect on embryos shortly after
the end of gastrulation, with some embryos showing elongation
defects and disorganized somites [46]. This observation indicates
that PDLIM5 has a crucial role in embryonic development.
This study aimed to evaluate the effects of decreased PDLIM5
levels on certain behaviors, specifically those related to mood
disorders, because significant but not robust evidence for mood
disorders in humans has been reported. We used Pdlim5 hetero
KO mice, because an increase or reduction of PDLIM5 expression
in human brains, peripheral lymphoblastoid cells, and lympho-
cytes has been reported to be linked with schizophrenia and mood
disorders [16,17,19,47]. Because differences in the size and weight
of the brain and body, or other anatomical abnormalities, were not
Figure 2. Effect of METH administration on locomotor activity and prepulse inhibition. Relative locomotor activity and prepulse inhibition
after acute (A, B, C) and chronic (D, E, F) administration of METH in Pdlim5+/+ and Pdlim5+/2 mice. Values are shown as mean 6 SD. * p,0.05 and
** p,0.01 by ANOVA.
doi:10.1371/journal.pone.0059320.g002
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found in the present study in Pdlim5 hetero KO C57BL/6J mice,
haploinsufficiency of Pdlim5 did not appear to cause the
developmental abnormalities. In addition, the behavior tests
(rota-rod, novelty-seeking, and social interaction tests) did not
show any significant difference in locomotion between Pdlim5+/+
and Pdlim5+/2 mice. Therefore, decreased Pdlim5 expression is
unlikely to have a major effect on mouse behavior. However, when
mice were treated with METH in the present study, significant
differences in locomotion and PPI were observed. For instance,
acute and chronic METH-induced hyperlocomotion and PPI
were less severe in Pdlim5+/2 than in Pdlim5+/+ mice. These
findings suggest that lower levels of PDLIM5 prevent the
development of a manic state or schizophrenia, which is consistent
with the speculation from the observations in human postmortem
brains, because higher levels of PDLIM5 have been reported in
the prefrontal cortex of patients with schizophrenia and bipolar
disorders [10,19]. The mechanisms for these findings are subject to
speculation. However, the transient inhibition of PKCe by
pretreatment with PKCe-TIP produced similar effects on loco-
motion to those observed in Pdlim5 hetero KO mice in response to
Figure 3. Effects of PKCe-TIP on locomotor activity and prepulse inhibition response to METH. Relative locomotor activity (A, B) and
prepulse inhibition (C) by the treatment of PKCe-TIP after chronic METH administration. Values are shown as mean 6 SD. P values are based on
ANOVA. * p,0.05 and ** p,0.01 by ANOVA.
doi:10.1371/journal.pone.0059320.g003
Figure 4. Effect of imipramine treatment on forced swimming.
Immobility time of Pdlim5 hetero KO and wild-type mice in the forced
swimming test with saline or chronic imipramine administration. Values
are shown as mean 6 SD. * p,0.05 and ** p,0.01 by ANOVA.
doi:10.1371/journal.pone.0059320.g004
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METH. These observations support the speculation that the
involvement of PDLIM5 in the behavioral response to METH is
partly via calcium or PKCe signaling.
A significant increase in the immobility time of forced
swimming test was observed in Pdlim5 hetero KO mice compared
to the wild-type mice. This observation could also be interpreted
as being consistent with observations in human peripheral
leukocytes. Iga and colleagues also reported that decreased
PDLIM5 levels returned to normal after 8 weeks of medication
in the peripheral lymphocytes of patients with depression [17].
The same group of authors reported an increased expression of
PDLIM5 in peripheral leukocytes in medication-free patients with
schizophrenia but not in patients administered antipsychotic
medication [16]. These reports raise the possibility that antipsy-
chotics reduce PDLIM5 expression levels, while antidepressants
increase PDLIM5 expression levels. Such a possibility is partially
supported by the findings obtained through the chronic admin-
istration of haloperidol and imipramine; haloperidol decreased
Pdlim5 expression levels in the prefrontal area, while chronic
administration of imipramine increased Pdlim5 expression levels in
the hippocampus area. However, chronic administration of
haloperidol also increased Pdlim5 expression levels in the
hippocampus and midbrain, indicating the presence of a complex
relationship between drugs and Pdlim5 expression. An alternative
possibility is that these drugs do not directly influence PDLIM5
expression, but that PDLIM5 levels are related to the psychiatric
state.
PDLIM5 may also be implicated in neural development. For
instance, in the present study, Pdlim5 expression levels increased in
the hippocampus of mice receiving chronic haloperidol or
imipramine treatment compared to the control. Adult hippocam-
pal neurogenesis has been implicated in antidepressant action
[48]. Adult treatment with haloperidol is reported to increase
dentate granule cell proliferation in the gerbil hippocampus [49],
and to promote the survival of stem cells in the rat hippocampus
[50]. Lasorella and colleagues reported that PDLIM5 is upregu-
lated during neural development, and that it contributes to the
differentiation of the nervous system through cytoplasmic seques-
tration of Id2, which binds to the PDLIM5 LIM domains [51].
The findings of the present study may support the possibility that
some antipsychotics influence Pdlim5 expression levels, and that
changes in Pdlim5 expression levels may contribute to the
worsening or alleviation of some symptoms. Because we did not
examine the brain of Pdlim52/2 embryos in this study, the effect
of the absence of PDLIM5 LIM domains on brain development
should be focused on in future studies.
This study was subject to several limitations, including a lack of
analyses of Pdlim52/2 mice, a lack of specificity of PKCe-TIP to
PDLIM5, a lack of measuring hypothalamic-pituitary-adrenocor-
tical axis activity parallel to the behavioral phenotypes, and
particularly limitations of a pharmacological model of bipolar
disorder mania by METH administration. Despite these limita-
tions, the present study indicates that the increased expression of
PDLIM5 may cause behavioral changes to patients with mania or
schizophrenia-like symptoms, whereas a decrease in its expression
may cause depression. In conclusion, our findings support that
PDLIM5 is involved in psychiatric disorders, including mood
disorders.
Figure 5. Relative Pdlim5 expression levels after METH, haloperidol and imipramine administrations in mice brains. Seven-week-old
C57BL/6J male mice were treated with an intraperitoneal injection (i.p.) of METH (3.0 mg/kg, once daily for 14 days) (A, B), haloperidol (1 mg/kg, once
daily for 49 days) (C), imipramine (20 mg/kg, once daily for 14 days) (D), or vehicle-saline. The upregulated Pdlim5 expression in the prefrontal cortex
of chronic METH-administered mice (A) was confirmed by a separate experiment using a different mice cohort (B). Values are shown as mean 6 SD.
* p,0.05 and ** p,0.01 by Student’s t test.
doi:10.1371/journal.pone.0059320.g005
Mood Disorders in Pdlim5 Knockout Mice
PLOS ONE | www.plosone.org 8 April 2013 | Volume 8 | Issue 4 | e59320
Supporting Information
Figure S1 Behavioral characteristics in Pdlim5 hetero
knockout mice. The rota-rod, novelty-seeking, social interac-
tion, locomotion, and prepulse inhibition tests were conducted in
Pdlim5+/+ and Pdlim5+/2 mice. These behaviors showed no
significant differences between the 2 genotype groups. Values are
shown as mean 6 SD.
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